- Home
- IEP vs BPMC Comparison
IEP vs BPMC Comparison
Compare IEP & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEP
- BPMC
- Stock Information
- Founded
- IEP 1987
- BPMC 2008
- Country
- IEP United States
- BPMC United States
- Employees
- IEP N/A
- BPMC N/A
- Industry
- IEP Auto Parts:O.E.M.
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- IEP Consumer Discretionary
- BPMC Health Care
- Exchange
- IEP Nasdaq
- BPMC Nasdaq
- Market Cap
- IEP 6.0B
- BPMC 5.9B
- IPO Year
- IEP 1987
- BPMC 2015
- Fundamental
- Price
- IEP $9.87
- BPMC $96.15
- Analyst Decision
- IEP
- BPMC Buy
- Analyst Count
- IEP 0
- BPMC 20
- Target Price
- IEP N/A
- BPMC $120.79
- AVG Volume (30 Days)
- IEP 1.0M
- BPMC 587.2K
- Earning Date
- IEP 11-08-2024
- BPMC 10-30-2024
- Dividend Yield
- IEP 35.51%
- BPMC N/A
- EPS Growth
- IEP N/A
- BPMC N/A
- EPS
- IEP N/A
- BPMC N/A
- Revenue
- IEP $10,055,000,000.00
- BPMC $434,415,000.00
- Revenue This Year
- IEP N/A
- BPMC $108.09
- Revenue Next Year
- IEP N/A
- BPMC $39.34
- P/E Ratio
- IEP N/A
- BPMC N/A
- Revenue Growth
- IEP N/A
- BPMC 100.93
- 52 Week Low
- IEP $9.72
- BPMC $72.24
- 52 Week High
- IEP $22.59
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- IEP 26.50
- BPMC 53.72
- Support Level
- IEP $10.01
- BPMC $91.88
- Resistance Level
- IEP $10.59
- BPMC $97.44
- Average True Range (ATR)
- IEP 0.30
- BPMC 2.65
- MACD
- IEP -0.01
- BPMC -0.27
- Stochastic Oscillator
- IEP 6.90
- BPMC 57.49
About IEP Icahn Enterprises L.P.
Icahn Enterprises LP is a provider of diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.